Relatlimab is a medication that is being studied for its potential to help the immune system fight cancer. It works by blocking a specific protein that can slow down the immune response. By blocking this protein, relatlimab may help the body’s immune system attack cancer cells more effectively. In this trial, it is being tested in combination with another medication to see if it can improve treatment outcomes for people with advanced liver cancer.

Nivolumab is a medication that helps the immune system recognize and attack cancer cells. It works by blocking a protein that prevents the immune system from attacking cancer cells. This can help the immune system to better identify and destroy cancer cells. In this trial, nivolumab is being used both on its own and in combination with another medication to see how well it works for people with advanced liver cancer who have not been treated with immune therapy before but have tried other cancer treatments.

Advanced Hepatocellular Carcinoma – Advanced Hepatocellular Carcinoma is a type of liver cancer that originates in the hepatocytes, the main type of liver cell. It is characterized by the uncontrolled growth of abnormal cells in the liver, leading to the formation of a tumor. As the disease progresses, the tumor may grow larger and spread to other parts of the liver or to other organs in the body. Symptoms may include abdominal pain, weight loss, and jaundice, which is a yellowing of the skin and eyes. The disease can cause liver dysfunction as it advances, affecting the liver’s ability to perform its normal functions. Over time, the cancer may invade blood vessels and other structures, complicating the condition further.